Cart
sales@molnova.com
2-Hydroxypyridine
CAS No. 142-08-5
2-Hydroxypyridine( —— )
Catalog No. M19561 CAS No. 142-08-5
2-Hydroxypyridine is the catalyst for generating β-oxopropyl carbonates from cyclic carbonates and alcohols and in the aminolysis of a polyglutamate.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 37 | In Stock |
|
| 500MG | 86 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2-Hydroxypyridine
-
NoteResearch use only, not for human use.
-
Brief Description2-Hydroxypyridine is the catalyst for generating β-oxopropyl carbonates from cyclic carbonates and alcohols and in the aminolysis of a polyglutamate.
-
Description2-Hydroxypyridine is the catalyst for generating β-oxopropyl carbonates from cyclic carbonates and alcohols and in the aminolysis of a polyglutamate.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number142-08-5
-
Formula Weight95.1
-
Molecular FormulaC5H5NO
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=c1cccc[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhu M et L. Efficient synthesis of biazoles by aerobic oxidative homocoupling of azoles catalyzed by a copper(I)/2-pyridonate catalytic system. Chem Commun (Camb). 2011 Dec 28;47(48):12876-8.
molnova catalog
related products
-
IRG1-IN-1
IRG1-IN-1, an itaconic acid derivative, inhibits Immune Response Gene 1 (IRG1) activity and is suitable for cancer, inflammation, and autoimmune disease research.
-
A2AR-agonist-1
A2AR-agonist-1 is a potent A2AR and ENT1 agonist (Ki: 4.39 and 3.47 for A2AR and ENT1. It targets the Adenosine A2A Receptor and Adenosine Transporter for Neuroprotection.
-
FFAGLDD TFA
FFAGLDD TFA is an MMP9 selective cleavage peptide, which is used for the cytoplasmic transfer of doxorubicin (DOX) to realize the controlled slow drug delivery and release.
